Bisfenol (A) una toxina a tener en cuenta en el enfermo renal en hemodiálisis

  • Enrique Bosch Panadero Fundacion Jimenez Diaz , Madrid
  • Sebastian Mas Fontao Fundacion Jimenez Diaz , Madrid
  • Alberto Ruiz Priego Fundacion Jimenez Diaz , Madrid
  • Jesús Egido Fundacion Jimenez Diaz , Madrid
  • Emilio González Parra Fundacion Jiménez Díaz , Madrid
Palabras clave: toxina urémica, bisfenol A, enfermedad crónica renal, disruptor endocrino, hemodiálisis.

Resumen

Muchas toxinas urémicas son originadas como consecuencia del catabolismo proteico por la flora intestinal. El metabolismo de aminoácidos aromáticos origina residuos de tipo fenólico. De estas toxinas, la más estudiada es el p-cresol, que se asocia a la función renal y daño vascular. El Bisfenol A (BPA) es una molécula exógena de características semejantes a estas toxinas urémicas aromáticas. El BPA es un disruptor endocrino estrogénico que se encuentra en latas de conserva, botellas de plástico, resinas epoxi y en algunos dializadores. Esta molécula se acumula en pacientes que tienen deteriorada la función renal. Estudios observacionales han demostrado que una exposición a BPA está vinculada, entre otras muchas, a lesión renal y cardiovascular en los seres humanos; en estudios en animales se ha descrito un vínculo causal. Los riñones con función renal normal excretan rápidamente BPA, pero una excreción insuficiente en pacientes con ERC da lugar a la acumulación del BPA en el organismo.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Enrique Bosch Panadero, Fundacion Jimenez Diaz , Madrid
PhD, Laboratorio Renal, Vascular y Diabetes, Madrid, España
Sebastian Mas Fontao, Fundacion Jimenez Diaz , Madrid
PhD, Centro de Investigación Biomédica en Red en Diabetes y enfermedades metabólicas asociadas (CIBERDEM), Madrid, España
Alberto Ruiz Priego, Fundacion Jimenez Diaz , Madrid
MD, PhD, Departamento de Nefrología e Hipertensión, Madrid, España, Red Española de Investigación Renal, Madrid, España
Jesús Egido, Fundacion Jimenez Diaz , Madrid
MD, PhD, Departamento de Nefrología e Hipertensión, Madrid, España, Red Española de Investigación Renal, Madrid, España
Emilio González Parra, Fundacion Jiménez Díaz , Madrid
MD, PhD, Facultad de Medicina, Universidad Autónoma de Madrid, España; Fundación Renal Íñigo Álvarez de Toledo,
Instituto Reina Sofía de Investigación en Nefrología, Madrid, España

Referencias

1. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman Breen C, et al. Cardiovascular Mortality Risk in Chronic Kidney Disease. JAMA [Internet]. 2005 [accedido 01 Jan 2000];293(14):1737. Disponible en: https://doi.org/10.1001/jama.293.14.1737

2. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol [Internet]. 2008 [accedido 01 Jan 2000];19(5):863-70.
Disponible en: https://doi.org/10.1681/ASN.2007121377

3. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A [Internet]. 2009 [accedido 01 Jan 2000];106(10):3698-703.
Disponible en: https://doi.org 10.1073/pnas.0812874106

4. Goldfarb DS, Modersitzki F, Asplin JR. A randomized, controlled trial oflactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol [Internet]. 2007 [accedido 01 Jan 2000];2(4):745-9. Disponible en: https://doi.org/10.2215/CJN.00600207

5. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis [Internet]. 2004 [accedido 01 Jan 2000]; 44(2):278-85. Disponible en: https://doi.org/10.1053/j.ajkd.2004.04.033

6. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P. Progress in Uremic Toxic Research: Protein-bound toxins Update 2009. Semin Dial [Internet]. 2009 [accedido 01 Jan 2000];22(4):334-9. Disponible en:
https://doi.org/10.1111j.1525-139X.2009.00576.x

7. Martinez AW, Recht NS, Hostetter TH, Meyer TW. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol [Internet]. 2005 [accedido 01 Jan 2000];16(11):3430-6.
Disponible en: https://doi.org/10.1681/ASN.2005030310

8. Meijers BKI, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int [Internet]. 2008 [accedido 01 Jan 2000];73(10):1174-80.
Disponible en: https://doi.org/10.1038ki.2008.31

9. Schmidt S, Westhoff TH, Krauser P, Zidek W, van der Giet M. The uraemic toxin phenylacetic acid increases the formation of reactive oxygen species in vascular smooth muscle cells. Nephrol Dial Transplant [Internet]. 2008 [accedido 01 Jan 2000];23(1):65-71.
Disponible en:https://doi.org/10.1093/ndt/gfm475

10. Yano S, Yamaguchi T, Kanazawa I, Ogawa N, Hayashi K, Yamauchi M, et al. The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. Nephrol Dial Transplant [Internet]. 2007 [accedido 01 Jan 2000];22(11):3160-5. Disponible en: https://doi.org/10.1093/ndt/gfm455

11. Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr Opin Nephrol Hypertens [Internet]. 2008 [accedido 01 Jun 2000];17(6):560-5.
Disponible en: https://doi.org/10.1097/MNH. 0b013e32830f45b6

12. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemost [Internet]. 2006 [accedido 01Jun 2000];4(3):566-73.
Disponible en: https://doi.org/10.1111j.1538-7836.2005.01780.x

13. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. KidneyInt [Internet]. 2003 [accedido 01 Jun 2000];63(5):1671–80. Disponible en: https://doi.org/10.1046/j.1523-1755.2003.00906.x

14. Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T, et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol[Internet]. 2003 [accedido 01 Jun 2000];95(3):e111-8. Disponible en: https://doi.org/10.1159/000074327

15. Meijers BKI, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant [Internet]. 2011 [accedido 01 Jun 2000];26(3):759-61.
Disponible en: https://doi.org10.1093/ndt/gfq818

16. Wu I-W, Hsu K-H, Lee C-C, Sun C-Y, Hsu H-J, Tsai C-J, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant [Internet]. 2011 [accedido 01 Jun 2000];26(3):938-47. Disponible en: https://doi.org/10.1093/ndt/gfq580

17. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol [Internet]. 2009 [accedido 01 Jun 2000];4(10):1551-8.
Disponible en: https://doi.org10.2215/CJN.03980609

18. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int [Internet]. 2006 [accedido 01 Jun 2000];69(10):1780-5. Disponible en: https://doi.org/10.1038/sj.ki.5000340

19. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J [Internet]. 2010 [accedido 01 Jun 2000];31(14):1771-9.
Disponible en: https://doi.org/10.1093/eurheartj/ehp574

20. Chiang C-K, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest [Internet]. 2011[accedido 01 Jun 2000];91(11):1564-71.
Disponible en: https://doi.org/10.1038 labinvest.2011.114

21. Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al. Indoxyl sulfate inducesskeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int [Internet]. 2007 [accedido 01 Jun 2000];71(8):738-43. Disponible en: https://doi.org/10.1038sj.ki.5002097

22. Dodds EC, Goldberg L, Lawson W, Robinson R. OEstrogenic Activity of Certain Synthetic Compounds. Nature [Internet].1938 [accedido 01 Jun 2000];141:247-8. Disponible en: https://doi.org/10.1038/141247b0

23. Casajuana N, Lacorte S. New methodology for the determination of phthalate esters, bisphenol A, bisphenol A diglycidyl ether, and nonylphenol in commercial whole milk samples. J Agric Food Chem [Internet]. 2004 [accedido 01 Jun 2000];52(12):3702-7. Disponible en: https://doi.org/10.1021/jf040027s

24. Thomson BM, Grounds PR. Bisphenol A in canned foods in New Zealand: an exposure assessment. Food Addit Contam [Internet]. 2005 [accedido 01 Jun 2000];22(1):65-72. Disponible en: https://doi. org/10.1080/02652030400027920

25. Dekant W, Volkel W. Human exposure to bisphenol A by biomonitoring: methods, results and assessment of environmental exposures. Toxicol Appl Pharmacol [Internet]. 2008 [accedido 01 Jun 2000];228(1):114-34. Disponible en: https://doi.org/10.1016 j.taap.2007.12.008

26. U.S. Food and Drug Administration. Draft Assessment of Bisphenol A for Use in Food Contract Applications [Internet]. 2008 [accedido 01 Jun 2000]:1-105. Disponible en: https://www.fda.gov/ohrms/dockets/ac/08 briefing/2008-0038b1_01_02_FDA%20BPA%20Draft%20Assessment.pd

27. Davidson I, Gallieni M, Saxena R, Dolmatch B. A patient centered decision making dialysis access algorithm. J Vasc Access [Internet]. 2007 [accedido 01 Jun 2000];8(2):59-68. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/17534790

28. Kataria A, Trasande L, Trachtman H. The effects of environmental chemicals on renal function. Nat Rev Nephrol [Internet]. 2015 [accedido 01 Jun 2000];11(10):610-25.
Disponible en: https://doi.org/10.1038nrneph.2015.94

29. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect [Internet]. 2005 [accedido 01 Jun 2000];113(4):391-5.
Disponible en: https://doi.org/10.1289ehp.7534

30. Cutanda F, Koch HM, Esteban M, Sanchez J, Angerer J, Castano A. Urinary levels of eight phthalate metabolites and bisphenol A in mother-hild pairs from two Spanish locations. Int J Hyg Environ Health [Internet]. 2015 [accedido 01 Jun 2000];218(1):47-57. Disponible en: https://doi.org10.1016/j.ijheh.2014.07.005

31. Murakami K, Ohashi A, Hori H, Hibiya M, Shoji Y, Kunisaki M, et al. Accumulation of bisphenol A in hemodialysis patients. Blood Purif [Internet]. 2007 [accedido 01 Jun 2000];25(3):290-4. Disponible en: https://doi.org/10.1159/000104869

32. Boeniger MF, Lowry LK, Rosenberg J. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review. Am Ind Hyg Assoc J [Internet]. 1993 [accedido 01 Jun 2000]; 54(10):615-27.
Disponible en: https://doi.org/10.108015298669391355134

33. Krieter DH, Canaud B, Lemke H-D, Rodriguez A, Morgenroth A, von Appen K, et al. Bisphenol A in chronic kidney disease. Artif Organs [Internet]. 2013 [accedido 01 Jun 2000];37(3):283-90. Disponible en: https://doi.org/10.1111/j.1525-1594.2012.01556.x

34. Kanno Y, Okada H, Kobayashi T, Takenaka T, Suzuki H. Effects of endocrine disrupting substance on estrogen receptor gene transcription in dialysis patients. Ther Apher Dial [Internet]. 2007 [accedido 01 Jun 2000]; 11(4):262–5.
Disponible en: https://doi.org/10.1111j.1744-9987.2007.00472.x

35. You L, Zhu X, Shrubsole MJ, Fan H, Chen J, Dong J, et al. Renal function, bisphenol A, and alkylphenols: results from the National Health and Nutrition Examination Survey (NHANES 2003-2006). Environ Health Perspect [Internet]. 2011 [accedido 01 Jun 2000];119(4):527-33. Disponible en: https://doi.org/10.1289/ehp.1002572

36. Li M, Bi Y, Qi L, Wang T, Xu M, Huang Y, et al. Exposure to bisphenol A is associated with low-grade albuminuria in Chinese adults. Kidney Int [Internet]. 2012 [accedido 01 Jun 2000];81(11):1131-9. Disponible en: https://doi.org/10.1038/ki.2012.6

37. Olea-Herrero N, Arenas MI, Munoz-Moreno C, Moreno-Gomez-Toledano R, Gonzalez-Santander M, Arribas I, et al. Bisphenol-A induces podocytopathy with proteinuria in mice. J Cell Physiol [Internet]. 2014 [accedido 01 Jun 2000];229(12):2057-66.
Disponible en: https://doi.org 10.1002/jcp.24665

38. Saura M, Marquez S, Reventun P, Olea-Herrero N, Arenas MI, Moreno-Gomez-Toledano R, et al. Oral administration of bisphenol A induces high blood pressure through angiotensin II/CaMKII-dependent uncoupling of eNOS. Faseb J [Internet]. 2014 [accedido 01 Jun 2000];28(11):4719-28.
Disponible en:https://doi.org/10.1096/fj.14-252460

39. Hu J, Yang S, Wang Y, Goswami R, Peng C, Gao R, et al. Serum bisphenol A and progression of type 2 diabetic nephropathy: a 6-year prospective study. Acta Diabetol [Internet]. 2015 [accedido 01 Jun 2000];52(6):1135-41.
Disponible en: https://doi.org/10.1007s00592-015-0801-5

40. Romero M, Ortega A, Izquierdo A, Lopez-Luna P, Bosch RJ. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy. Nephrol Dial Transplant [Internet]. 2010 [accedido 01 Jun 2000]; 25(8):2447-57. Disponible en: https://doi.org/10.1093/ndt/gfq104

41. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int [Internet]. 2002 [accedido 01 Jun 2000]; 62(3):901-13. Disponible en: https://doi.org/10.1046/j.1523-1755.2002.00528.x

42. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int [Internet]. 1999 [accedido 01 Jun 2000]; 56(2):393-405.
Disponible en: https://doi.org/10.1046/j.1523-1755.1999.00590.x

43. Hengstler JG, Foth H, Gebel T, Kramer P-J, Lilienblum W, Schweinfurth H, et al. Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit Rev Toxicol [Internet]. 2011 [accedido 01 Jun 2000];41(4):263-91.
Disponible en:https://doi.org/10.3109/10408444.2011.558487

44. Haishima Y, Hayashi Y, Yagami T, Nakamura A. Elution of bisphenol-A from hemodialyzers consisting of polycarbonate and polysulfone resins. J Biomed Mater Res [Internet]. 2001 [accedido 01 Jun 2000];58(2):209-15. Disponible en: https://doi.org/10.1002/1097-4636(2001)58:2<209:AID-JBM1009>3.0.CO;2-7

45. Shintani H. Determination of the endocrine disrupter bisphenol-A in the blood of uremia patients treated by dialysis. Chromatographia [Internet]. 2001 [accedido 01 Jun 2000];(53):331-3. Disponible en: https://doi.org/10.1007/BF02490435

46. Yamasaki H, Nagake Y, Makino H. Determination of bisphenol a in effluents of hemodialyzers. Nephron [Internet]. 2001 [accedido 01 Jun 2000];88(4):376-8. Disponible en: https://doi.org/10.1159/000046023

47. Sugimura K, Naganuma T, Kakiya Y, Okada C, Sugimura T, Kishimoto T. Endocrine-disrupting chemicals in CAPD dialysate and effluent. Blood Purif [Internet]. 2001 [accedido 01 Jun 2000];19(1):213.
Disponible en: https://doi.org/10.1159/000014473

48. Scientific Committee on Emerging and Newly Identified Health Risk. Opinion on The safety of the use of bisphenol A in medical devices. 2015 [accedido 01 Jun 2000]. Disponible en: https://doi.org/10.2772/75546

49. Bosch-panadero E, Mas S, Sanchez-ospina D, Camarero V. The Choice of Hemodialysis Membrane Affects Serum Bisphenol A Levels. 2015;1–10.

50. European Food Safety Authority. Bisphenol A [Internet]. [lugar desconocido]: European Food Safety Authority; 2015 [accedido 01 Jun 2000]. Disponible en: http://www.efsa.europa.eu/en/topics/topic/
bisphenol.
Publicado
2017-03-15
Cómo citar
Bosch Panadero, E., Mas Fontao, S., Ruiz Priego, A., Egido, J., & González Parra, E. (2017). Bisfenol (A) una toxina a tener en cuenta en el enfermo renal en hemodiálisis. Revista Colombiana De Nefrología, 4(1), 57-68. https://doi.org/10.22265/acnef.4.1.256
Sección
Artículo de revisión